Get started
Finch Therapeutics Group, Inc.Finch Therapeutics Group, Inc.Finch Therapeutics Group, Inc.

Finch Therapeutics Group, Inc.

No trades
See on Supercharts
Overview
Financials
News Discussions Technicals Seasonals

FNCH fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Finch Therapeutics Group, Inc. engages in the development of microbiome drugs. Its platform includes Human-First Discovery that enables reverse translation from clinical data to engineer the composition of the microbiome based on disease-modifying mechanisms. The company was founded by Mark Smith, Andrew Noh, Tom Borody and Zain Kassam in 2014 and is headquartered in Boston, MA.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
FNCH has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company